We are live on ! Find out more
VTVT icon

vTv Therapeutics
VTVT

24 hedge funds and large institutions have $3.76M invested in vTv Therapeutics in 2022 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 10 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.05% less ownership

Funds ownership: 0.24% → 0.19% (-0.05%)

17% less funds holding

Funds holding: 29 → 24 (-5)

43% less capital invested

Capital invested by funds: $6.55M → $3.76M (-$2.78M)

63% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 8

90% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 10

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

Holders
24
Holders Change
-5
Holders Change %
-17.24%
% of All Funds
0.38%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
3
Increased
1
Reduced
10
Closed
8
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
IC
Ikarian Capital
Texas
+$32.2K
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$17.3K
3
Renaissance Technologies
Renaissance Technologies
New York
+$8.57K
4
TRCT
Tower Research Capital (TRC)
New York
+$5.84K

Top Sellers

Rank Fund Capital Flow
1
EC
EcoR1 Capital
California
-$830K
2
Morgan Stanley
Morgan Stanley
New York
-$129K
3
Citadel Advisors
Citadel Advisors
Florida
-$94K
4
VF
Virtu Financial
New York
-$94K
5
Rafferty Asset Management
Rafferty Asset Management
New York
-$69K
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$1.27M – – –
SB
2
Samsara BioCapital
California
$1.18M – – –
IC
3
Ikarian Capital
Texas
$536K +$32.2K +1,075 +6%
Geode Capital Management
4
Geode Capital Management
Massachusetts
$250K -$60 -2 -0%
CIM
5
CIM Investment Management
Pennsylvania
$115K -$13.8K -461 -10%
Millennium Management
6
Millennium Management
New York
$89K -$16.9K -563 -15%
BlackRock
7
BlackRock
New York
$80K -$1.95K -65 -2%
BFM
8
Boothbay Fund Management
New York
$56K – – –
State Street
9
State Street
Massachusetts
$40K -$270 -9 -0.6%
Northern Trust
10
Northern Trust
Illinois
$29K – – –
Morgan Stanley
11
Morgan Stanley
New York
$25K -$129K -4,302 -83%
Susquehanna International Group
12
Susquehanna International Group
Pennsylvania
$17K +$17.3K +578 New
V
13
Veritable
Delaware
$15K – – –
TSS
14
Two Sigma Securities
New York
$13K -$18.4K -614 -57%
SWM
15
Spire Wealth Management
Virginia
$11K -$30 -1 -0.3%
EGM
16
Engineers Gate Manager
New York
$11K – – –
Renaissance Technologies
17
Renaissance Technologies
New York
$8K +$8.57K +286 New
TRCT
18
Tower Research Capital (TRC)
New York
$6K +$5.84K +195 New
SFCL
19
Strengthening Families & Communities LLC
Massachusetts
$5K – – –
Osaic Holdings
20
Osaic Holdings
Arizona
$1K – – –
PA
21
Parallel Advisors
California
$1K – – –
Wells Fargo
22
Wells Fargo
California
$1K – – –
BNP Paribas Financial Markets
23
BNP Paribas Financial Markets
France
$238 -$359 -12 -60%
EC
24
EcoR1 Capital
California
– -$830K -20,858 Closed
VF
25
Virtu Financial
New York
– -$94K -2,362 Closed
1
2

VTVT Hedge Fund Activity: Q1 2022 in Review

24 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in vTv Therapeutics (VTVT) for Q1 2022, worth a combined $3.76M — down 43% from $6.55M a quarter earlier.

Sellers outnumbered buyers: 8 funds closed out of VTVT and 3 opened new positions — a net loss of 5 holders — while 10 trimmed existing stakes and 1 added.

The largest buyer was Ikarian Capital, adding an estimated $32.2K. The largest seller was EcoR1 Capital, exiting entirely with an estimated $830K sold.

  • 24 institutional investors held vTv Therapeutics (VTVT) as of Q1 2022, down from 29 in Q4 2021.
  • Funds reported $3.76M of vTv Therapeutics stock for Q1 2022, down 43% quarter-over-quarter.
  • 3 funds opened new vTv Therapeutics positions in Q1 2022 and 8 closed out, a net change of -5 holders.
  • The largest vTv Therapeutics buyer in Q1 2022 was Ikarian Capital, an estimated $32.2K added.
  • The largest vTv Therapeutics seller in Q1 2022 was EcoR1 Capital, an estimated $830K sold.

Based on aggregated 13F filings for Q1 2022.